Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultevursen sham-controlled phase 2 study in USH2A exon 13 retinitis pigmentosa
NL-OMON59807Phase 2Withdrawn
- Sponsor
- Laboratoires Théa
- Start
- Apr 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Annualized percent change from baseline in ellipsoid zone width. Planned start Apr 2025; status: withdrawn.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NL-OMON59807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59807.